Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | DRD3 | P35462 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18848281 | 0.81 | CTSK (0.39) | NAAACTSKSMN1; SMN2LMNA | |
| SCHEMBL18848361 | 0.81 | CTSK (0.39) | NAAACTSKSMN1; SMN2LMNA | |
| SCHEMBL18848226 | 0.81 | CTSK (0.39) | NAAACTSKSMN1; SMN2LMNA | |
| SCHEMBL1884858 | 0.80 | CTSK (0.38) | NAAACTSKSMN1; SMN2LMNASIGMAR1 | |
| SCHEMBL13943478 | 0.80 | NAAA (0.39) | NAAACTSKSMN1; SMN2LMNAEPHX2 | |
| SCHEMBL3883112 | 0.80 | CTSK (0.34) | CTSKSMN1; SMN2LMNA | |
| SCHEMBL1884824 | 0.79 | NAAA (0.35) | NAAACTSKSMN1; SMN2LMNAEPHX2 | |
| SCHEMBL18848348 | 0.79 | CHRNB2 (0.39) | NAAACTSK | |
| SCHEMBL18848250 | 0.79 | CHRNB2 (0.39) | NAAACTSK | |
| SCHEMBL18848276 | 0.79 | CHRNB2 (0.39) | NAAACTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7566738-B2 | Acyloxyalkyl carbamate prodrugs of sulfinic acids, methods of synthesis, and use | XENOPORT, INC. (US) | 2009-07-28 | — | — | US | disclosed |
| US-20080242723-A1 | ACYLOXYALKYL CARBAMATE PRODRUGS OF SULFINIC ACIDS, METHODS OF SYNTHESIS, AND USE | XENOPORT, INC. (US) | 2008-10-02 | — | — | US | disclosed |
| US-20060111439-A1 | Acyloxyalkyl carbamate prodrugs of sulfinic acids, methods of synthesis, and use | XENOPORT, INC. | 2006-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242723-A1 | ACYLOXYALKYL CARBAMATE PRODRUGS OF SULFINIC ACIDS, METHODS OF SYNTHESIS, AND USE | ASS1, APEH, ACMSD | NAAA 24/4885CTSK 1480/4885SMN1; SMN2 210/4885 |
| US-20060111439-A1 | Acyloxyalkyl carbamate prodrugs of sulfinic acids, methods of synthesis, and use | ASS1, APEH, ACMSD | NAAA 24/4885CTSK 1480/4885SMN1; SMN2 210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.